NEW YORK, June 25, 2014 /PRNewswire/ -- Amarin
Corporation, plc (Nasdaq: AMRN), today announced a national
partnership with Rick Harrison, star
of the hit television show "Pawn Stars®," in launching
Lower My Trigs™, a national awareness campaign about seeking
treatment for very high triglycerides (VHTG) (> 500 mg/dL), a
problem faced by up to four million Americans. Amarin has engaged
Harrison as a spokesperson for the campaign to inform patients and
family members, their physicians and other health care
professionals about the health risks of very high triglycerides and
the importance of patients discussing available treatment options
with their physician.
Rick Harrison, known for his keen
assessment of the value of rare and unique items – from
16th century manuscripts to Elvis memorabilia – shares
his journey from diagnosis to treatment, including his road to
learning more about treatment myths and physician-supervised
options. Rick provides his story in a video at
www.lowermytrigs.com.
"A pawn store's success is based on finding out the real story
about any item before making a decision – to lower my risk. When it
comes to my own health, I apply that same wisdom. So, I did my
research, and was surprised to learn that there are hundreds of
dietary fish oil supplements and most of these products contain DHA
which can actually raise bad cholesterol in patients like
me," shared Rick Harrison. "I
realized that I needed to work with a doctor who understood the
differences."
Rick's physician recommended that he exercise, diet and take
Vascepa® (icosapent ethyl) capsules. Vascepa is
available by prescription only and there is no other product
available that contains only the omega-3 fatty acid, EPA. EPA-only
Vascepa is also the only omega-3 prescription product approved for
use by the FDA in adult patients with triglyceride levels of at
least 500 mg/dL that is not associated with increases in bad
cholesterol.
"As a patient with very high triglycerides, Rick has applied the
same level of energy and dedication toward improving his health as
he does to making the right decisions for his business. As a
result, he and his doctor have agreed on EPA-only Vascepa as the
appropriate choice for Rick to treat his very high triglyceride
levels," said John Thero, President
and Chief Executive Officer of Amarin. "By partnering with Rick on
the Lower My Trigs campaign, it is our hope to greatly
increase awareness of very high triglyceride levels and the
importance of seeking a doctor's guidance to control this
condition. We hope that the millions of other patients with very
high triglycerides will learn more about their condition and
actively participate in their successful treatment."
In addition to patient and physician resources, visitors to
www.lowermytrigs.com can also save on Vascepa, the treatment Rick's
physician prescribed, with a Vascepa Savings Card, if eligible.
About Vascepa® (icosapent ethyl)
capsules
Vascepa® (icosapent ethyl) capsules, known in
scientific literature as AMR101, is a highly pure-EPA omega-3
prescription product in a 1 gram capsule.
Indications and Usage
- Vascepa (icosapent ethyl) is indicated as an adjunct to diet to
reduce triglyceride (TG) levels in adult patients with severe (>
500 mg/dL) hypertriglyceridemia.
- The effect of Vascepa on the risk for pancreatitis and
cardiovascular mortality and morbidity in patients with severe
hypertriglyceridemia has not been determined.
Important Safety Information for Vascepa
- Vascepa is contraindicated in patients with known
hypersensitivity (e.g., anaphylactic reaction) to Vascepa or any of
its components and should be used with caution in patients with
known hypersensitivity to fish and/or shellfish.
- The most common reported adverse reaction (incidence > 2%
and greater than placebo) was arthralgia (2.3% for Vascepa, 1.0%
for placebo).
FULL VASCEPA PRESCRIBING INFORMATION CAN BE FOUND
AT WWW.VASCEPA.COM.
Vascepa has been approved for use by the FDA as an
adjunct to diet to reduce triglyceride levels in adult patients
with severe (> 500 mg/dL) hypertriglyceridemia. Vascepa is
under various stages of development for potential use in other
indications that have not been approved by the FDA. Nothing in
this press release should be construed as marketing the use of
Vascepa in any indication that has not been approved by
the FDA.
About Amarin
Amarin Corporation plc is a biopharmaceutical company
focused on the commercialization and development of therapeutics to
improve cardiovascular health. Amarin's product
development program leverages its extensive experience in lipid
science and the potential therapeutic benefits of polyunsaturated
fatty acids. Vascepa® (icosapent
ethyl), Amarin's first FDA approved product, is
an ultra-pure, EPA-only, omega-3 fatty acid product available by
prescription. For more information about Vascepa visit
www.vascepa.com. For more information about Amarin visit
www.amarincorp.com.
Forward-Looking Statements
This press release contains forward-looking statements,
including statements about the potential efficacy, safety and
therapeutic benefits of Amarin's product, Amarin's clinical trial
results, including statements about the clinical importance of
certain parameters and the impact of Vascepa on such parameters.
These forward-looking statements are not promises or guarantees and
involve substantial risks and uncertainties. Among the factors that
could cause actual results to differ materially from those
described or projected herein include uncertainties associated
generally with research and development, clinical trials and
related regulatory reviews and approvals, including the risk that
historical clinical trial results may not be predictive of future
results in replicated in larger patient populations and that
studied lipid parameters may not have clinically meaningful effect
or support regulatory approvals. A further list and description of
these risks, uncertainties and other risks associated with an
investment in Amarin can be found in Amarin's filings with the U.S.
Securities and Exchange Commission, including its most recent
Quarterly Report on Form 10-Q. Existing and prospective investors
are cautioned not to place undue reliance on these forward-looking
statements, which speak only as of the date hereof. Amarin
undertakes no obligation to update or revise the information
contained in this press release, whether as a result of new
information, future events or circumstances or otherwise.
Availability of other information about Amarin
Investors and others should note that we communicate with our
investors and the public using our company website
(www.amarincorp.com), our investor relations website
(http://www.amarincorp.com/investor-splash.html), including but not
limited to investor presentations and investor FAQs, Securities and
Exchange Commission filings, press releases, public conference
calls and webcasts. The information that we post on these channels
and websites could be deemed to be material information. As a
result, we encourage investors, the media, and others interested in
Amarin to review the information that we post on these channels,
including our investor relations website, on a regular basis. This
list of channels may be updated from time to time on our investor
relations website and may include social media channels. The
contents of our website or these channels, or any other website
that may be accessed from our website or these channels, shall not
be deemed incorporated by reference in any filing under the
Securities Act of 1933.
PAWN STARS® is a trademark of A&E Television
Networks, LLC. The Amarin group of companies is not affiliated or
associated with A&E Television Networks, LLC.
Amarin contact information
Michael Farrell
Investor Relations and Corporate Communications
Amarin Corporation plc
908-719-1315
investor.relations@amarincorp.com
Photo - http://photos.prnewswire.com/prnh/20140623/120643
Logo - http://photos.prnewswire.com/prnh/20140623/120642
Logo - http://photos.prnewswire.com/prnh/20140623/120644
SOURCE Amarin Corporation, plc